Persistence of patients receiving topical glaucoma monotherapy in an Asian population

Archives of Ophthalmology

Volumn 129, Issue 5, 2011, Pages 643-648

  Quek, Desmond T L ^a   Ong, Geok Teng ^a   Perera, Shamira A ^a   Lamoureux, Ecosse L ^a,b   Aung, Tin ^a,c  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL MALEATE; TRAVOPROST;

ADULT; ARTICLE; ASIAN; CHINESE; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERSISTENT GLAUCOMA; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGAPORE;

ADMINISTRATION, TOPICAL; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DATABASES, FACTUAL; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PHARMACY SERVICE, HOSPITAL; RETROSPECTIVE STUDIES; SINGAPORE;

EID: 79955778697     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.345     Document Type: Article

References (29)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267.
2. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713. (Pubitemid 34620348)
3. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279. (Pubitemid 36105431)
4. Kass MA, Gordon M, Morley RE Jr, Meltzer DW, Goldberg JJ. Compliance with topical timolol treatment. Am J Ophthalmol. 1987;103(2):188-193. (Pubitemid 17005483)
5. Gurwitz JH, Yeomans SM, Glynn RJ, Lewis BE, Levin R, Avorn J. Patient noncompliance in the managed care setting: the case of medical therapy for glaucoma. Med Care. 1998;36(3):357-369. (Pubitemid 128456379)
6. Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care. 2002;8(10)(suppl):S271-S277. (Pubitemid 34918728)
7. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther. 2003;25(4):1172-1185. (Pubitemid 36532585)
8. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol. 2004;137(1)(suppl):S3-S12. (Pubitemid 38091629)
9. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol. 2004;137(1)(suppl):S13-S16. (Pubitemid 38091630)
10. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598-606.
11. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794-811.
12. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288(22):2880-2883. (Pubitemid 35425074)
13. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research: a comprehensive review. J Clin Pharm Ther. 2001;26(5):331-342. (Pubitemid 32989555)
14. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(suppl 1):S57-S68.
15. Schwartz GF, Platt R, Reardon G, Mychaskiw MA. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology. 2007;114(4):648-652. (Pubitemid 46483699)
16. Spooner JJ, Bullano MF, Ikeda LI, et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care. 2002;8(10)(suppl):S262-S270. (Pubitemid 34918727)
17. Dasgupta S, Oates V, Bookhart BK, Vaziri B, Schwartz GF, Mozaffari E. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care. 2002;8(10)(suppl):S255-S261. (Pubitemid 34918726)
18. Day DG, Schacknow PN, Sharpe ED, et al. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2004;20(5):383-392. (Pubitemid 39441778)
19. Diestelhorst M, Schaefer CP, Beusterien KM, et al. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study. Eur J Ophthalmol. 2003;13(suppl 4):S21-S29.
20. Rait JL, Adena MA. Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data. Clin Experiment Ophthalmol. 2007;35(7):602-611. (Pubitemid 47491216)
21. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol. 2003;13(suppl 4):S44-S52.
22. Zhou Z, Althin R, Sforzolini BS, Dhawan R. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol. 2004;88(11):1391-1394. (Pubitemid 39424716)
23. Platt R, Reardon G, Mozaffari E. Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. Am J Ophthalmol. 2004;137(1)(suppl):S17-S23. (Pubitemid 38091631)
24. Wilensky J, Fiscella RG, Carlson AM, Morris LS, Walt J. Measurement of persistence and adherence to regimens of IOP-lowering glaucomamedications using pharmacy claims data. Am J Ophthalmol. 2006;141(1)(suppl):S28-S33. (Pubitemid 43028477)
25. Owen CG, Carey IM, de Wilde S, Whincup PH, Wormald R, Cook DG. Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994-2005. Eye (Lond). 2009;23(5):1098-1110.
26. Rouland JF, Le Pen C; Ophthalmologists of the Glaucoma Study. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. Eur J Ophthalmol. 2003;13(suppl 4):S5-S20.
27. Lee PP, Walt JG, Chiang TH, Guckian A, Keener J. A gap analysis approach to assess patient persistence with glaucoma medication. Am J Ophthalmol. 2007;144(4):520-524. (Pubitemid 47429624)
28. Higginbotham EJ. Ocular Hypertension Treatment Study. Arch Ophthalmol. 2009;127(2):213-215.
29. Feiner L, Piltz-Seymour JR; Collaborative Initial Glaucoma Treatment Study. Collaborative Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthalmol. 2003;14(2):106-111. (Pubitemid 36584231)